Novo Nordisk | NVO - Des Atouts

Prix De L'Action
37.61
Variation Quotidienne
0.70 1.90%
Mensuellement
-5.43%
Annuel
-42.25%
Q2 Prévisions
35.05




Des Atouts Changement Date
ANI Pharmaceuticals USD 1.44B 32.22M 2025-12
Aurora Cannabis CAD 775.29M 18.43M 2025-12
Bausch Health Companies USD 26.37B 458M 2025-12
Bristol-Myers Squibb USD 96.89B 2.21B 2025-09
Canopy Growth CAD 1.11B 36.35M 2025-12
Corcept Therapeutics USD 836.65M 13.04M 2025-12
Drreddys Laboratories INR 6.26B 161.9M 2025-12
Eli Lilly USD 112.48B 2.46B 2025-12
GlaxoSmithKline GBP 61.12B 221M 2025-12
Merck USD 129.55B 12.02B 2025-09
Nektar Therapeutics USD 280.41M 20.94M 2025-12
Novartis USD 110.95B 3.66B 2025-12
Novo Nordisk DKK 542.9B 30.61B 2025-12
Novo Nordisk DKK 76.18B 412.98B 2025-06
Pacira USD 1.26B 32.66M 2025-12
Perrigo USD 8.54B 1.55B 2025-12
Phibro Animal Health USD 1.41B 20.03M 2025-12
Prestige Brands USD 3.49B 52.46M 2025-12
Sanofi EUR 126.81B 2.99B 2025-12
Supernus Pharmaceuticals USD 1.45B 32.89M 2025-12
Zoetis USD 15.47B 308M 2025-12